Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash & Equivalents: 2019-2025

Historic Cash & Equivalents for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $298.9 million.

  • IDEAYA Biosciences' Cash & Equivalents fell 25.32% to $298.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.9 million, marking a year-over-year decrease of 25.32%. This contributed to the annual value of $84.4 million for FY2024, which is 46.26% down from last year.
  • According to the latest figures from Q3 2025, IDEAYA Biosciences' Cash & Equivalents is $298.9 million, which was up 160.74% from $114.6 million recorded in Q2 2025.
  • In the past 5 years, IDEAYA Biosciences' Cash & Equivalents registered a high of $400.3 million during Q3 2024, and its lowest value of $49.1 million during Q2 2022.
  • For the 3-year period, IDEAYA Biosciences' Cash & Equivalents averaged around $163.5 million, with its median value being $130.0 million (2025).
  • In the last 5 years, IDEAYA Biosciences' Cash & Equivalents soared by 285.63% in 2021 and then crashed by 59.57% in 2022.
  • Over the past 5 years, IDEAYA Biosciences' Cash & Equivalents (Quarterly) stood at $92.0 million in 2021, then dropped by 25.44% to $68.6 million in 2022, then spiked by 128.78% to $157.0 million in 2023, then tumbled by 46.26% to $84.4 million in 2024, then decreased by 25.32% to $298.9 million in 2025.
  • Its Cash & Equivalents was $298.9 million in Q3 2025, compared to $114.6 million in Q2 2025 and $130.0 million in Q1 2025.